

SAFETY DATA SHEET

Product Name: Diphenhydramine Hydrochloride Injection

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Address	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
Hospira, Inc., Non-Emergency	224 212-2000
Product Name	Diphenhydramine Hydrochloride Injection
Synonyms	2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride.

2. HAZARD(S) IDENTIFICATION

Emergency Overview Diphenhydramine Hydrochloride Injection is a solution containing diphenhydramine hydrochloride, an antihistamine used for relief of symptoms associated with allergies or colds; it is also used for the treatment of symptoms associated with motion sickness. In the workplace, this material should be considered potentially irritating to eyes and the respiratory tract. Based on clinical use, possible target organs include skin, eyes, central nervous system, and gastrointestinal system.

U.S. OSHA GHS Classification

Physical Hazards	Hazard Class	Hazard Category
	Not Classified	Not Classified
Health Hazards	Hazard Class	Hazard Category

Label Element(s)

Pictogram



Signal Word	Warning
Hazard Statement(s)	May cause damage to organs through prolonged or repeated exposure
Precautionary Statement(s) Prevention	Do not breathe vapor or spray. Wash hands thoroughly after handling.
Response	Get medical attention if you feel unwell.
	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.



3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name	Diphenhydramine Hydrochloride			
Chemical Formula	$C_{17}H_{21}NO \bullet HCl$			
Component	Approximate Percent by Weight	CAS Number	RTECS Number	
Diphenhydramine Hydrochloride	5	147-24-0	KR700000	

 Dipnennydramine Hydrochloride
 5
 147-24-0
 KR7000

 Non-hazardous ingredients include Water for Injection. Sodium hydroxide or hydrochloric acid may be added to adjust the pH.
 147-24-0
 KR7000

4. FIRST AID MEASURES

Eye Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/ supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	None anticipated for this aqueous product.
Fire & Explosion Hazard	None anticipated for this aqueous product.
Extinguishing Media	As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.
Special Fire Fighting Procedures	No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and DisposalIsolate area around spill. Put on suitable protective clothing and equipment as
specified by site spill control procedures. Absorb the liquid with suitable material and
clean affected area with soap and water. Dispose of spill materials according to the
applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling	No special handling required for hazard control under conditions of normal product use.
Storage	No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.
Special Precautions	No special precautions required for hazard control.



8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure Limits				
Component	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL	
Diphenhydramine Hydrochloride	8-hr TWA: Not	8-hr TWA: Not	8-hr TWA: Not	8-hr TWA: Not	
Dipiteninydrannine Hydrochionde	Established	Established	Established	Established	
Notes: OSHA PEL: US Occupational S: ACGIH TLV: American Confer AIHA WEEL: Workplace Enviro EEL: Employee Exposure Limit TWA: 8-hour Time Weighted A	ence of Governmental Indust onmental Exposure Level				
Respiratory Protection	Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.				
Skin Protection	If skin contact with the second secon	he product formulation	is likely, the use of l	atex or nitrile gloves	
Eye Protection	Eye protection is normally not required during intended product use. However, if ey contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.				
Engineering Controls	Engineering controls are normally not needed during the normal use of this product.				

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	The product is a clear liquid
Odor	NA
Odor Threshold	NA
рН	Between 4 and 6.5
Melting point/Freezing Point	NA
Initial Boiling Point/Boiling Point Range	NA
Flash Point	NA
Evaporation Rate	NA
Flammability (solid, gas)	NA
Upper/Lower Flammability or Explosive Limits	NA
Vapor Pressure	NA
Vapor Density (Air =1)	NA
Relative Density	NA
Solubility	Freely soluble in water and alcohol
Partition Coefficient: n-octanol/water	NA
Auto-ignition Temperature	NA
Decomposition Temperature	NA
Viscosity	NA



10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Not determined
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and hydrogen chloride.
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Diphenhydramine Hydrochloride	100	LD50	Oral	500, 700 64, 164 280	mg/kg mg/kg mg/kg	Rat Mouse Guinea Pig
Diphenhydramine Hydrochloride	100	LD50	Intravenous	35 20 10 18 24	mg/kg mg/kg mg/kg mg/kg mg/kg	Rat Mouse Rabbit Hamster Dog

LD 50: Dosage that produces 50% mortality.

Occupational Exposure Potential	Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None anticipated from normal handling of this product. In clinical use, adverse effects may include sedation, sleepiness, dyspnea, breathing difficulty, disturbed coordination, gastrointestinal upset and thickened bronchial secretion. Allergic dermatitis is not uncommon in topically applied H1-blockers. Over dosage can result in atropine like signs (dry-mouth, dilated pupils, flushing and gastrointestinal symptoms) and cycles of CNS depression and stimulation (hallucinations, incoordination and convulsions).
Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/ Corrosion	None anticipated from normal handling of this product.
Ocular Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product.
Reproductive Effects	None anticipated from normal handling of this product. Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have shown no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride.
Mutagenicity	Long-term studies in animals to determine mutagenic potential have not been conducted.



11. TOXICOLOGICAL INFORMATION: continued

Carcinogenicity	Long-term studies in animals to determine the carcinogenic potential have not been conducted.		
Carcinogen Lists	IARC: Not listed	NTP: Not listed	OSHA: Not listed
Specific Target Organ Toxicity – Single Exposure	NA		
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs include skin, eyes, central nervous system and gastrointestinal system.		

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.
Notes:	

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS Proper Shipping Name Hazard Class UN Number Packing Group Reportable Quantity	Not regulated NA NA NA NA NA
ICAO/IATA STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
IMDG STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA

Notes: DOT - US Department of Transportation Regulations



15. REGULATORY INFORMATION

US TSCA Status	Exempt.
US CERCLA Status	Not listed
US SARA 302 Status	Not listed
US SARA 313 Status	Not listed
US RCRA Status	Not listed
US PROP 65 (Calif.)	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*	*In the EU, classificat mixtures, such as med the finished state, inter	icinal products as o	defined in Directive 2	certain substances and 2001/83/EC, which are in
Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA
Prevention	Do not breathe vapor or spray. Wash hands thoroughly after handling.			
Response	Get medical attention	if you feel unwell.		
	IF IN EYES: Rinse ca if present and easy to c attention.			. Remove contact lenses, persists, get medical
EU Classification*	*Medicinal products a Preparations Directive	-	e requirements of the	EU Dangerous
Classification(s) Symbol Indication of Danger Risk Phrases Safety Phrases	NA NA NA S23: Do not breathe va S24: Avoid contact wi S25: Avoid contact wi S37/39 Wear suitable	th the skin th eyes	e protection.	



16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD_{50}	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average
MSDS Coordinator:	Hospira GEHS
Date Prepared:	October 17, 2012
Date Revised:	June 02, 2014

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.